Patent ID: 8062838

Claim:
A method of predicting a patient's sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising: assessing in a tumor sample from the patient, the level of the epithelial biomarkers E-cadherin or Brk expressed by the tumor cells; and determining that if the tumor cells express the epithelial biomarkers at the level found in any of the epithelial tumor cells H441, H358 or H292 that are sensitive to an IGF-1R kinase inhibitor, sensitivity to growth inhibition by an IGF-1R kinase inhibitor is predicted, or if the tumor cells express the epithelial biomarker at the level found in the mesenchymal-like tumor cells SW1573 or H460 that are relatively insensitive to an IGF-1R kinase inhibitor, lack of sensitivity to growth inhibition by an IGF-1R Kinase inhibitor is predicted.